Director/PDMR Shareholding

RNS Number : 4364S
Cambridge Cognition Holdings PLC
24 September 2014
 

24 September 2014

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

 

Directors/PDMR Shareholding

 

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests has been notified of the following transactions by Directors, which took place on 23 September 2014.

 

Nick Kerton, Chief Executive Officer, purchased 58,000 ordinary shares at a price of 59.8 pence each. Following this notification, Mr Kerton now has a total beneficial interest of 72,285 Ordinary Shares representing 0.43% of the issued share capital of the Company.

 

Nick Walters, Chief Financial Officer, purchased 47,000 ordinary shares at a price of 59.8 pence each. Following this notification, Mr Walters has a total beneficial interest of 47,000 Ordinary Shares representing 0.28% of the issued share capital of the Company.

 

Cambridge Cognition's capital consists of 16,930,556 Ordinary Shares with voting rights. The Company does not hold any Ordinary Shares in Treasury.

 

 

 

 

Enquiries:

 

Cambridge Cognition Holdings plc

www.cambridgecognition.com

Nick Kerton, Chief Executive Officer

Tel: 01223 810 700

Nick Walters, Chief Financial Officer




finnCap Ltd (Nomad and Broker)

Tel: 020 7220 0500

Matthew Robinson/Henrik Persson/Simon Hicks

(Corporate Finance)

Elizabeth Johnson

(Corporate Broking)



Walbrook PR Ltd

Tel: 020 7933 8780 or camcog@walbrookpr.com

Paul McManus

Mob: 07584 391 303

Lianne Cawthorne

Mob: 07584 391 303

 

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products.  The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic  scientists  in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function.  In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products under the Cantab mobile brand, to improve the monitoring, management and maintenance of cognitive health and wellbeing.  Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families. 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBXLLLZKFLBBB
UK 100

Latest directors dealings